A detailed history of Susquehanna International Group, LLP transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 49,755 shares of OCUP stock, worth $52,740. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,755
Previous 46,577 6.82%
Holding current value
$52,740
Previous $71,000 8.45%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.19 - $2.07 $3,781 - $6,578
3,178 Added 6.82%
49,755 $65,000
Q2 2024

Aug 15, 2024

BUY
$1.51 - $2.23 $6,020 - $8,891
3,987 Added 9.36%
46,577 $71,000
Q1 2024

May 07, 2024

BUY
$1.89 - $3.27 $38,527 - $66,658
20,385 Added 91.8%
42,590 $85,000
Q4 2023

Feb 14, 2024

SELL
$2.59 - $3.64 $87,529 - $123,013
-33,795 Reduced 60.35%
22,205 $66,000
Q3 2023

Nov 14, 2023

BUY
$3.35 - $4.33 $187,600 - $242,480
56,000 New
56,000 $187,000
Q1 2023

May 16, 2023

SELL
$3.01 - $3.85 $46,507 - $59,486
-15,451 Reduced 51.16%
14,751 $55,000
Q4 2022

Feb 14, 2023

SELL
$2.04 - $3.53 $13,037 - $22,560
-6,391 Reduced 17.47%
30,202 $106,000
Q3 2022

Nov 14, 2022

SELL
$1.82 - $2.79 $14,632 - $22,431
-8,040 Reduced 18.01%
36,593 $74,000
Q2 2022

Aug 15, 2022

SELL
$1.8 - $3.25 $13,482 - $24,342
-7,490 Reduced 14.37%
44,633 $86,000
Q1 2022

May 16, 2022

SELL
$2.75 - $4.39 $31,229 - $49,852
-11,356 Reduced 17.89%
52,123 $169,000
Q4 2021

Feb 14, 2022

BUY
$3.4 - $5.19 $77,129 - $117,735
22,685 Added 55.61%
63,479 $237,000
Q3 2021

Nov 15, 2021

SELL
$3.84 - $5.38 $70,571 - $98,873
-18,378 Reduced 31.06%
40,794 $210,000
Q2 2021

Aug 11, 2021

BUY
$4.24 - $6.57 $250,889 - $388,760
59,172 New
59,172 $312,000

Others Institutions Holding OCUP

About Ocuphire Pharma, Inc.


  • Ticker OCUP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,579,800
  • Market Cap $21.8M
  • Description
  • Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...
More about OCUP
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.